Bristol-Myers Squibb
Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.
BMY Key Statistics
Stock Snapshot
Bristol-Myers Squibb(BMY) stock is priced at $65.82, giving the company a market capitalization of 133.78B. It carries a P/E multiple of 14.89 and pays a dividend yield of 3.71%.
During the trading session on 2026-08-20, Bristol-Myers Squibb(BMY) shares reached a daily high of $67.52 and a low of $65.46. At a current price of $65.82, the stock is +0.6% higher than the low and still -2.5% under the high.
Trading activity shows a volume of 9.49M, compared to an average daily volume of 9.2M.
The stock's 52-week range extends from a low of $42.52 to a high of $68.64.
The stock's 52-week range extends from a low of $42.52 to a high of $68.64.
BMY News
Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter,...
...
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO By Trey Thoelcke Published Aug 20, 10:40AM EDT Quick Read SPTX's Glyph prodrug pl...
Analyst ratings
58%
of 31 ratingsMore BMY News
Michael Yee, an analyst from UBS, maintained the Buy rating on Bristol-Myers Squibb. The associated price target remains the same with $80.00. Unlock powerful...
Bristol-Myers Squibb (BMY) is in focus after two related announcements. The FDA granted accelerated approval for its new multiple myeloma drug ZENBEXUS, and the...
Bristol-Myers Squibb stock has delivered a 40.6% 1 year return, while both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currentl...
Key Points AbbVie demonstrates resilient revenue growth fueled by its next-generation immunology and aesthetics portfolio. Bristol-Myers Squibb maintains high...
William Blair analyst Matt Phipps has maintained their neutral stance on BMY stock, giving a Hold rating on August 4. Unlock powerful investing tools with TipR...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.